Table 1.
Demographic and clinical characteristics of the study population.
| Characteristic | Sample size | CN | MCI | AD | P-value |
|---|---|---|---|---|---|
| N | 881 | 311 | 386 | 184 | |
| Age, median (IQR) | 881 | 66.0 (58.9–70.0) | 70.5 (65.1–75.5) | 71.0 (63.4–77.0) | <0.001* |
| Male sex, N (%) | 881 | 133 (42.8%) | 181 (46.9%) | 86 (46.7%) | 0.509 |
| MMSE, median (IQR) | 878 | 29.0 (28.0–30.0) | 26.5 (25.0–28.0) | 22.0 (18.0–25.0) | <0.001* |
| APOE ε4+, N (%) | 881 | 118 (37.9%) | 186 (48.2%) | 112 (60.9%) | <0.001* |
| Aβ+, N (%) | 881 | 93 (30.0%) | 245 (63.5%) | 165 (89.7%) | <0.001* |
| P-tau+, N (%) | 787 | 42 (19.1%) | 203 (53.0%) | 128 (69.6%) | <0.001* |
| T-tau+, N (%) | 791 | 45 (20.1%) | 221 (57.6%) | 149 (81.4%) | <0.001* |
CN, normal cognition; MCI, mild cognitive impairment; AD, Alzheimer’s disease; IQR, interquartile range; MMSE, mini-mental state examination; APOE, apolipoprotein E; Aβ, amyloid-β; p-tau, phosphorylated-tau; t-tau, total tau.
*
p < 0.05.